Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERS 
Cerus Corporation (CERS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CERS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.67
1 Year Target Price $4.67
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.24% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 241.54M USD | Price to earnings Ratio - | 1Y Target Price 4.67 |
Price to earnings Ratio - | 1Y Target Price 4.67 | ||
Volume (30-day avg) 5 | Beta 1.63 | 52 Weeks Range 1.12 - 2.23 | Updated Date 09/17/2025 |
52 Weeks Range 1.12 - 2.23 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.81% | Operating Margin (TTM) -6.53% |
Management Effectiveness
Return on Assets (TTM) -3.67% | Return on Equity (TTM) -35.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 262413480 | Price to Sales(TTM) 1.25 |
Enterprise Value 262413480 | Price to Sales(TTM) 1.25 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA -13.19 | Shares Outstanding 191699008 | Shares Floating 172427314 |
Shares Outstanding 191699008 | Shares Floating 172427314 | ||
Percent Insiders 3.34 | Percent Institutions 73.82 |
Upturn AI SWOT
Cerus Corporation
Company Overview
History and Background
Cerus Corporation, founded in 1991, focuses on developing and commercializing the INTERCEPT Blood System, a technology designed to inactivate bloodborne pathogens in donated blood components intended for transfusion.
Core Business Areas
- Blood Safety: Development and commercialization of the INTERCEPT Blood System for platelets, plasma, and red blood cells to reduce the risk of transfusion-transmitted infections.
Leadership and Structure
William 'Obi' Greenman is the President and Chief Executive Officer. The company has a typical corporate structure with departments for research and development, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Competitors: Macopharma
- INTERCEPT Blood System for Platelets: Designed to inactivate a broad range of pathogens in platelet components. Market share is estimated around 70% in pathogen reduction technology for platelets in Europe and a smaller portion in the US, growing with adoption. Competitors include Macopharma's Mirasol system. Revenue is proprietary but significant to Cerus' overall revenue.
- Competitors: Macopharma
- INTERCEPT Blood System for Plasma: Inactivates pathogens in plasma for transfusion. Similar market share to platelets in Europe, growing in US. Revenue is proprietary but significant to Cerus' overall revenue.
- Competitors: Macopharma
- INTERCEPT Blood System for Red Blood Cells: Inactivates pathogens in Red Blood Cells. Early stages of launch with potential in regions with high risk of mosquito borne disease. Market share is still small but growing as hospitals adopt this product. Competitors include Macopharma. Revenue is low and growing.
Market Dynamics
Industry Overview
The blood transfusion industry is focused on ensuring the safety and availability of blood products. Pathogen reduction technologies are increasingly important due to emerging infectious diseases and the need to reduce transfusion-transmitted infections.
Positioning
Cerus is a leader in pathogen reduction technology for blood components, primarily focused on platelets and plasma, and expanding into red blood cells. They aim to be the standard of care for blood safety.
Total Addressable Market (TAM)
The estimated TAM for blood safety is several billion dollars annually. Cerus is well positioned to capture a significant portion with increased adoption of their INTERCEPT Blood System.
Upturn SWOT Analysis
Strengths
- Proprietary technology with strong patent protection
- Established presence in Europe
- Growing adoption in the US
- Focus on critical healthcare need (blood safety)
Weaknesses
- Reliance on a single product line
- Regulatory hurdles in some markets
- High cost of implementation for hospitals
- Long sales cycles
Opportunities
- Expansion into new geographic markets
- Development of new applications for INTERCEPT technology
- Increasing awareness of blood safety risks
- Partnerships with blood banks and hospitals
Threats
- Competition from alternative blood safety technologies
- Pricing pressures from healthcare providers
- Regulatory changes
- Emergence of new bloodborne pathogens
Competitors and Market Share
Key Competitors
- Macopharma (Private)
Competitive Landscape
Cerus has a strong competitive position in pathogen reduction for platelets and plasma. Macopharma, also privately held, is its primary competitor. Cerus' advantage lies in its established presence and growing adoption in the US.
Growth Trajectory and Initiatives
Historical Growth: Cerus has demonstrated revenue growth over the past few years, driven by increased adoption of the INTERCEPT Blood System, with year-over-year revenue growth varying between 10% and 20%.
Future Projections: Analysts project continued revenue growth for Cerus, driven by expansion into new markets and increased adoption of the INTERCEPT Blood System, with projected annual revenue growth in the range of 15% to 25% over the next 3-5 years.
Recent Initiatives: Recent initiatives include expanding the INTERCEPT Blood System into red blood cells, securing regulatory approvals in new markets, and strengthening partnerships with blood banks and hospitals.
Summary
Cerus Corporation is a key player in blood safety, driven by its INTERCEPT Blood System. It has a strong foothold in Europe and growing acceptance in the US. Regulatory hurdles and competition pose challenges. Future growth depends on expanding into new markets and applications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cerus Corporation
Exchange NASDAQ | Headquaters Concord, CA, United States | ||
IPO Launch date 1997-01-30 | President, CEO & Chairman Mr. William M. Greenman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 614 | Website https://www.cerus.com |
Full time employees 614 | Website https://www.cerus.com | ||
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.